topic

166 Mucosal-associated invariant T-cells (MAIT) in pancreatic cancer
Jéssica Kamiki, Patrícia António, Pedro Noronha, Carolina Condeço, Georgia Paraschoudi, Eric De Sousa, Andreia Maia, Mireia Castillo-Martin, Antonio Beltran, Carlos Carvalho, Joana Lérias, Markus Maeurer

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A99; DOI: 10.1136/jitc-2020-SITC2020.0166
167 B-cell-based vaccination elicit potent immunity against glioblastoma
Catalina Lee-Chang, Jason Miska, David Hou, Aida Rashidi, Peng Zhang, Rachel Burga, Crag Horbinski, Roger Stupp, Maciej Lesniak

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A99-A101; DOI: 10.1136/jitc-2020-SITC2020.0167
170 Microfluidics cell squeezing enables potent cellular vaccines in murine models through direct cytosolic loading and direct CD8 T cell priming
Emrah Ozay, Matthew Booty, Katarina Blagovic, David Soto, Olivia Pryor, Adam Stockmann, Disha Subramanya, Kelly Volk, Armon Sharei, Howard Bernstein, Defne Yarar, Katherine Seidl, Scott Loughhead

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A102; DOI: 10.1136/jitc-2020-SITC2020.0170
174 An ex vivo tumoroid model of fresh patient tumors (3D-ACT) to assess efficacy of cellular therapy in immuno-oncology
Stephen Iwanowycz, Jared Ehrhart, Mibel Pabon, Tina Pastoor, Jenny Kreahling, Soner Altiok

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A104; DOI: 10.1136/jitc-2020-SITC2020.0174
241 Clinical outcomes of metastatic melanoma patients with liver metastases treated with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab
Vincent Ma, Kent Griffith, Jessica Waninger, Stephanie Daignault-Newton, Leslie Fecher, Ajjai Alva, Christopher Lao

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A143-A144; DOI: 10.1136/jitc-2020-SITC2020.0241
243 Real world exposure survival relationship of pembrolizumab in metastatic melanoma
Vishal Navani, Moira Graves, Giovana Marchett, Hiren Mandaliya, Nikola Bowden, Andre Van der Westhuizen

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A144-A145; DOI: 10.1136/jitc-2020-SITC2020.0243
246 Clinicopathologic and genomic correlates of tumor mutational burden and its impact on PD-(L)1 inhibition efficacy in non-small cell lung cancer according to different PD-L1 expression subgroups
Biagio Ricciuti, Navin Mahadevan, Renato Umeton, Joao Alessi, Andrew Polio, Natalie Vokes, Giulia Leonardi, Elizabeth Aguilar, Gonzalo Recondo, Giuseppe Lamberti, Marissa Lawrence, Pasi Janne, Eliezer Van Allen, Lynette Sholl, Mark Awad

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A147-A149; DOI: 10.1136/jitc-2020-SITC2020.0246
250 SEA-TGT is a nonfucosylated antibody with distinct and amplified effector function activity that leverages the dependencies of anti-TIGIT anti-tumor activity upon Fc? R engagement
Alyson Smith, Weiping Zeng, William Siegall, Bryan Grogan, Jane Haass, Amber Blackmarr, Robert Thurman, Scott Peterson, Shyra Gardai

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A151; DOI: 10.1136/jitc-2020-SITC2020.0250
252 Immune-related adverse events associated with immune checkpoint inhibitor therapy are associated with enhanced survival and disease-specific incidence
Eric Vick, Inas Abuali, Andrew Kelleher, Sarah Ludvigsen, Nathanael Moore, Nicholas Arias, Shuchi Gulati, Trisha Wise-Draper

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A152-A153; DOI: 10.1136/jitc-2020-SITC2020.0252
254 CTLA-4 blockade promotes Treg glucose metabolism and reduces Treg functional stability in glycolysis-defective tumors
Roberta Zappasodi, Inna Serganova, Ivan Cohen, Masatomo Maeda, Yasin Senbabaoglu, Masahiro Shindo, Rachana Maniyar, Mayuresh Mane, Avigdor Leftin, McLane Watson, Svena Verma, Matthew Lubin, Myat Kyaw Ko, Arnab Ghosh, Mohsen Abu-Akeel, Ellen Ackerstaff, Jason Koutcher, Ping-Chih Ho, Greg Delgoffe, Ronald Blasberg, Jedd Wolchok, Taha Merghoub

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A153-A154; DOI: 10.1136/jitc-2020-SITC2020.0254

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages